5 results  1 of 1 

1 MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors
Wen An, Ju-Seop Kang, Sukjoong Oh, Ang Tu
Korean J Physiol Pharmacol.2023;27(3):241-256.   Published online 2023 May 1     DOI: http://dx.doi.org/10.4196/kjpp.2023.27.3.241
      
2 Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
Jae Won Yoo
Blood Res.2023;58(S1):S20-S28.   Published online 2023 March 9     DOI: http://dx.doi.org/10.5045/br.2023.2023026
      
3 Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?
Woo-Baek Chung, Jong-Chan Youn, Ho-Joong Youn
Korean Circ J.2020;50(9):743-753.   Published online 2020 May 27     DOI: http://dx.doi.org/10.4070/kcj.2020.0158
      
4 Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
Yongxian Hu, Jiasheng Wang, Chengfei Pu, Kui Zhao, Qu Cui, Guoqing Wei, Wenjun Wu, Lei Xiao, Yang Xiao, Jinping Wang, Zhao Wu, He Huang
Cancer Res Treat.2018;50(4):1462-1466.   Published online 2018 February 5     DOI: http://dx.doi.org/10.4143/crt.2017.473
      
5 Current Perspectives on Emerging CAR-Treg Cell Therapy: Based on Treg Cell Therapy in Clinical Trials and the Recent Approval of CAR-T Cell Therapy
Koeun Kang, Junho Chung, Jaeseok Yang, Hyori Kim
J Korean Soc Transplant.2017;31(4):157-169.   Published online 2017 December 31     DOI: http://dx.doi.org/10.4285/jkstn.2017.31.4.157
      

 1 of 1